Organisation paid for research Program year 2025 Source: CMS Open Payments

American Research Corp Inc

Neither a doctor nor a teaching hospital

Research payments

$3,529,089

33 payments

Through program year 2025, American Research Corp Inc is reported as receiving $3,529,089 in research payments, across 33 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $686,946 7
2024 Research $643,824 6
2023 Research $804,767 8
2022 Research $547,790 5
2021 Research $421,994 3
2020 Research $264,924 2
2019 Research $158,844 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,215,777 31 payments
  2. Provepharm Inc. $313,312 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of Ly3437943 in Participants With Hepatic Impairment Compared With Healthy Participants $861,748 2 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (Nash) $719,206 6 payments
  3. Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment $407,297 2 payments
  4. Pvp-2016005 $313,312 2 payments
  5. A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of Ly3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, Or Severe Hepatic Impairment $213,615 3 payments
  6. Open-Label, Nonrandomized, Single-Dose, Parallel-Group, Safety, Tolerance, and Pharmacokinetic Study of Loxo-292 Administered to Fasted Hepatically Impaired Male and Female Subjects and Fasted Matched-Control Healthy Subjects $192,639 2 payments
  7. Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment $175,794 4 payments
  8. A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, Or Severe Hepatic Impairment $159,154 1 payment
  9. A Phase 1 Multicenter Parallel Single-Dose Open-Label Single-Period Study of Ly3502970 in Participants With Normal Hepatic Function and Participants With Mild Moderate Or Severe Hepatic Impairment $152,731 2 payments
  10. A Parallel-Group Single-Dose Phase 1 Open-Label Study to Investigate the Pharmacokinetics of Ly3437943 in Participants With Hepatic Impairment Compared With Healthy Participants $98,365 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record